PharmaVentures http://www.pharmatelevision.com A PharmaTelevision Channel en PharmaVentures Ltd 2009 PharmaVentures Ltd enquiries@pharmaventures.com http://images.pharmaventures.com/ptv/tfr.jpg http://www.pharmatelevision.com/ Businessno PharmaVentures LtdIn this edition of ‘The Financial Report’ brought to you by PharmaVentures Business Review, Fintan Walton talks to Sam Fazeli, Managing Director of European Equity Research at PiperJaffray.In this edition of ‘The Financial Report’ brought to you by PharmaVentures Business Review, Fintan Walton talks to Sam Fazeli, Managing Director of European Equity Research at PiperJaffray.In this edition of ‘The Financial Report’ brought to you by PharmaVentures Business Review, Fintan Walton talks to Sam Fazeli, Managing Director of European Equity Research at PiperJaffray. http://media.pharmatelevision.com/174.m4v Tue, 16 Sep 2008 00:00:00 GMTBusinessNo PharmaVentures LtdIn this Financial Report, the top Executives of ValiRx discuss their latest Financial Results, explain how they maintain shareholder value in spite of losses and hits on its share prices – a challenge faced in the global biotech industry – and its strategic course to continue to develop an R&D program which ensures future return for its investors. Several new and exciting products are discussed including GeneICE and Vali101, and the executives explain the strategy they employ to both balance the cost of developing these drugs and hedging their risks to ensure early return to investors.In this Financial Report, the top Executives of ValiRx discuss their latest Financial Results, explain how they maintain shareholder value in spite of losses and hits on its share prices – a challenge faced in the global biotech industry – and its strategic course to continue to develop an R&D program which ensures future return for its investors. Several new and exciting products are discussed including GeneICE and Vali101, and the executives explain the strategy they employ to both balance the cost of developing these drugs and hedging their risks to ensure early return to investors.In this Financial Report, the top Executives of ValiRx discuss their latest Financial Results, explain how they maintain shareholder value in spite of losses and hits on its share prices – a challenge faced in the global biotech industry – and its strategic course to continue to develop an R&D program which ensures future return for its investors. Several new and exciting products are discussed including GeneICE and Vali101, and the executives explain the strategy they employ to both balance the cost of developing these drugs and hedging their risks to ensure early return to investors. http://media.pharmatelevision.com/160.m4v Thu, 31 Jul 2008 00:00:00 GMTBusinessNo